Topics
- Factors limiting cell line qualification
- A more cultured approach to vaccine production
- Optimising mammalian cell lines for vaccines
- Mammalian cell sustainability
- Will cell culture dominate vaccine production
- The potential of novel and alternative cell lines
Who should Attend
Attendees from Big Biotech, Big Pharma, Specialised Biotech, Small and Medium pharma, Platform Technology Providers, EQMs, Academia research, Contract Service providers, Venture Capitalists, Government and regulatory affairs.
